首页> 美国卫生研究院文献>Clinical Cardiology >Rationale and Design of LAPLACE‐2: A Phase 3 Randomized Double‐Blind Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

【2h】

Rationale and Design of LAPLACE‐2: A Phase 3 Randomized Double‐Blind Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

机译：LAPLACE-2的基本原理和设计：一项3期随机双盲安慰剂和依泽替米贝控制的试验评估依伐洛单抗在高胆固醇血症患者中的背景他汀类药物治疗的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Clinical Cardiology
作者
Jennifer G. Robinson; William J. Rogers; Bettina S. Nedergaard; Jonathan Fialkow; Joel M. Neutel; David Ramstad; Ransi Somaratne; Jason C. Legg; Patric Nelson; Rob Scott; Scott M. Wasserman; Robert Weiss;
展开▼
作者单位

展开▼
年(卷),期 2014(37),4
年度 2014
页码 195–203
总页数 9
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词

相似文献

外文文献
中文文献

1. Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy [J] . Jennifer G. Robinson MD MPH, William J. Rogers MD, Bettina S. Nedergaard MD PhD, Clinical cardiology. . 2014,第4期

机译：LAPLACE-2的原理和设计：3期，随机，双盲，安慰剂和依泽替米贝控制的试验，评价依伏洛单抗对高胆固醇血症患者的背景他汀类药物治疗的疗效和安全性
2. Design and rationale of the LAPLACE-TIMI 57 trial: A phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK 9 in subjects with hypercholesterolemia on background statin therapy [J] . KohliP., DesaiN.R., GiuglianoR.P., Clinical cardiology. . 2012,第7期

机译：LAPLACE-TIMI 57试验的设计和基本原理：II期，双盲，安慰剂对照研究，PCSK 9单克隆抗体抑制剂对高胆固醇血症受试者接受他汀类药物背景的疗效和耐受性
3. Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy [J] . Payal Kohli MD, Nihar R. Desai MD MPH, Robert P. Giugliano MD SM, Clinical cardiology. . 2012,第7期

机译：LAPLACE-TIMI 57试验的设计和原理：背景锡汀治疗，II期，双盲，安慰剂对照研究PCSK9单克隆抗体抑制剂对高胆固醇血症患者的疗效和耐受性
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. Efficacy of the Chinese herbal formula CUF2 in the treatment of childhood asthma: Animal experiment, in vitro study and randomized, double-blinded, placebo-controlled clinical trial. [D] . Wong, Yeuk Oi. 2006

机译：中药配方CUF2在治疗儿童哮喘中的功效：动物实验，体外研究以及随机，双盲，安慰剂对照的临床试验。
6. Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II Double‐Blind Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy [O] . Payal Kohli, Nihar R. Desai, Robert P. Giugliano, 2012

机译：LAPLACE‐TIMI 57试验的设计和原理：背景锡汀治疗II期双盲安慰剂对照研究PCSK9单克隆抗体抑制剂对高胆固醇血症患者的疗效和耐受性
7. Rationale and design of LAPLACE-2:a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy [O] . Robinson, Jennifer G, Rogers, William J, Nedergaard, Bettina S, 2014

机译：LapLaCE-2的基本原理和设计：3期，随机，双盲，安慰剂和依泽替米贝对照试验，评估evolocumab对高胆固醇血症患者背景他汀类药物治疗的疗效和安全性

Rationale and Design of LAPLACE‐2: A Phase 3 Randomized Double‐Blind Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

著录项

相似文献

相关主题

期刊订阅